Abstract
Purpose
Olprinone, a phosphodiesterase type III inhibitor, is a strong inotrope and vasodilator that does not increase oxygen consumption and is often used during weaning from cardiopulmonary bypass (CPB). To control the pharmacological effects of olprinone, pharmacokinetic information is essential; however, there is little published information on the pharmacokinetics of olprinone in a large population. Therefore, the purpose of this study was to determine olprinone pharmacokinetic parameters in a large population undergoing cardiac surgery with CPB.
Methods
Olprinone was infused at a rate of 0.2 μg/kg/min when weaning from CPB was started. Whole blood samples were periodically obtained to determine the olprinone concentrations using high-performance liquid chromatography. Measured olprinone concentrations were analyzed with a one-compartment model via a population approach.
Results
A total of 86 blood samples from 26 patients were used for pharmacokinetic analysis. The calculated clearance, volume of distribution (V d), and elimination half-life were 378 ml/min, 40.7 l, and 97.1 min, respectively. Olprinone clearance depended on weight and creatinine clearance, whereas V d depended only on weight.
Conclusion
We investigated the pharmacokinetic parameters of olprinone in patients undergoing cardiac surgery with CPB. Olprinone clearance depended on weight and creatinine clearance, whereas V d depended only on weight. When olprinone is infused according to the recommended dosing regimen, it takes more than 60 min to reach the target concentration (20 ng/ml). However, there is a possibility that a lower concentration is sufficient for weaning from CPB in combination with a continuous infusion of dopamine.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
George M, Lehot JJ, Estanove S. Haemodynamic and biological effects of intravenous milrinone in patients with a low cardiac output syndrome following cardiac surgery: multicentre study. Eur J Anaesthesiol Suppl. 1992;5:31–4.
Mizushige K, Ueda T, Yukiiri K, Suzuki H. Olprinone: a phosphodiesterase III inhibitor with positive inotropic and vasodilator effects. Cardiovasc Drug Rev. 2002;20:163–74.
Young RA, Ward A. Milrinone. A preliminary review of its pharmacological properties and therapeutic use. Drugs. 1988;36:158–92.
Monrad ES, Baim DS, Smith HS, Lanoue AS. Milrinone, dobutamine, and nitroprusside: comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failure. Circulation. 1986;73:III168–74.
Adachi H, Tanaka H. Effects of a new cardiotonic phosphodiesterase III inhibitor, olprinone, on cardiohemodynamics and plasma hormones in conscious pigs with heart failure. J Cardiovasc Pharmacol. 1997;29:763–71.
Sasayama S, Asanoi H, Ishizaka S. Mechanics of contraction and relaxation of the ventricle in experimental heart failure produced by rapid ventricular pacing in the conscious dog. Eur Heart J 1991;12(suppl C):35–41
Yamada T, Takeda J, Katori N, Tsuzaki K, Ochiai R. Hemodynamic effects of milrinone during weaning from cardiopulmonary bypass: comparison of patients with a low and high prebypass cardiac index. J Cardiothorac Vasc Anesth. 2000;14:367–73.
Orime Y, Shiono M, Hata H, Yagi S, Tsukamoto S, Okumura H, Kimura S, Hata M, Sezai A, Obana M, Sezai Y. Effects of phosphodiesterase inhibitors after coronary artery bypass grafting. Jpn Circ J. 1999;63:117–22.
Arata H, Sasaki H, Ohsaka M, Sasaki Y, Hayakawa H, Tomono Y, Morishita N. A phase 1 study of E-1020: intravenous injection (in Japanese). Jpn J Clin Pharmacol Ther. 1990;21:613–21.
Mori M, Nishi S, Asada A. Pharmacokinetics and pharmacodynamics of olprinone after cardiac surgery (in Japanese). Osaka City Med J. 2004;50:1–8.
Product Note: “Coretec.®” Eizai Co., Ltd.
Kimata S, Hirosawa K, Kasanuki H, Takano T, Serizawa T, Shinoyama S, Kumata T, Hori S, Hiramori K. Clinical evaluation of E-1020 in patients with acute heart failure (in Japanese). Rinsho to Kenkyu. 1992;69:2260–74.
Murakami R, Ishibashi Y, Morioka S, Moriyama K. Comparison of E-1020 and dobutamine in patients with acute heart failure (in Japanese). Rinsho to Kenkyu. 1993;70:1265–72.
Onomoto M, Tsuneyoshi I, Yonetani A, Suehiro S, Matsumoto K, Sakata R, Kanmura Y. Differential pharmacologic sensitivities of phosphodiesterase-3 inhibitors among human isolated gastroepiploic, internal mammary, and radial arteries. Anesth Analg. 2005;101:950–956 (table of contents).
Das PA, Skoyles JR, Sherry KM, Peacock JE, Fox PA, Woolfrey SG. Disposition of milrinone in patients after cardiac surgery. Br J Anaesth. 1994;72:426–9.
Benotti JR, Lesko LJ, McCue JE, Alpert JS. Pharmacokinetics and pharmacodynamics of milrinone in chronic congestive heart failure. Am J Cardiol. 1985;56:685–9.
Butterworth JF 4th, Hines RL, Royster RL, James RL. A pharmacokinetic and pharmacodynamic evaluation of milrinone in adults undergoing cardiac surgery. Anesth Analg. 1995;81:783–92.
Hirabayashi Y, Igarashi T, Saitoh K, Fukuda H, Suzuki H, Shimizu R. Comparison of the effects of amrinone, milrinone and olprinone in reversing bupivacaine-induced cardiovascular depression. Acta Anaesthesiol Scand. 2000;44:1128–33.
Iribe G, Yamada H, Matsunaga A, Yoshimura N. Effects of the phosphodiesterase III inhibitors olprinone, milrinone, and amrinone on hepatosplanchnic oxygen metabolism. Crit Care Med. 2000;28:743–8.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Tsubokawa, T., Ishizuka, S., Fukumoto, K. et al. Population pharmacokinetics of olprinone in patients undergoing cardiac surgery with cardiopulmonary bypass. J Anesth 27, 243–250 (2013). https://doi.org/10.1007/s00540-012-1505-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00540-012-1505-4